COMPARATIVE STUDY OF CONCURRENT CHEMORADIATION USING PACLITAXEL IN TWO HISTOPATHOLOGICAL SUBTYPES (SQUAMOUS CELL CARCINOMA/ADENOCARCINOMA) OF UNRESECTABLE NON-SMALL CELL LUNG CANCER
DOI:
https://doi.org/10.11603/ijmmr.2413-6077.2021.2.12253Keywords:
unresectable, concurrent, adenocarcinoma, squamous cellAbstract
Background. Lung cancer is still a global burden and with rising population and increasing life expectancy the incidence of lung cancer is still on the rise.
Objective. To compare the treatment response and toxicity of weekly paclitaxel in locally advanced unresectable non-small cell lung cancer (NSCLC), when administered concurrently with external beam radiation to the chest in two different histopathological types – adenocarcinoma and squamous cell carcinoma.
Methods. A prospective randomised control trial was conducted in 60 NSCLC patients who were divided into two arms; adenocarcinoma and squamous cell carcinoma arm. All patients were treated with chemoradiation with concurrent paclitaxel 60 mg/m2. Data were evaluated with SPSS version 21.0 for windows with p-value <0.05.
Results. Haematological toxicity was the most common side effects evident from the third week of chemotherapy. At the end of 1 month of treatment, two (6.7%) patients had complete response in Arm A and one (3.3%) patient had complete response in Arm B. One (3.3%) patient had disease progression in Arm A and two patients progressed in Arm B. At 7 months post treatment three (10%) patients had complete response in both Arm A and Arm B. Four (13.3%) patients had disease progression in Arm A and ten (33.4%) patients progressed in Arm B.
Conclusions. Paclitaxel can be used as an alternative chemotherapeutic agent to the standard cisplatin. However, further studies with larger sample size are required to confirm the findings.
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin 2018;68(6):394–424.
https://doi.org/10.3322/caac.21492.
Collins LG, Haines C, Perkel R, Enck RE. Lung Cancer: Diagnosis and Management. Am Fam Physician 2007;75(1):56-63.
Schrump DS, Carter D, Kelsey CR, Marks LB, Giaccone G. Non-small cell lung cancer. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. Cancers Principles and Practice of Oncology. 9th edition. Philadelphia: Lippincott Williams & Wilkins, Wolters Kluwer business; 2011.p.799-847.
Pathak Ak, Bhutani M, Mohan A, Guleria R, Bal S, Kochupillai V. Non-small lung cancer (NSCLC): Current Status and Future Prospects. Indian J Chest Dis Allied Sci 2004;46(3):191-03.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC (American Joint Committee on Cancer). Cancer Staging Manual. Philadelphia, PA: Springer, 2010:133.
Pritchard SB, Anthony PS. Chemotherapy plus Radiotherapy Compared with Radiotherapy Alone in the Treatment of Locally Advanced, Unresectable, Non-Small-Cell Lung Cancer. A Meta-Analysis. Ann Intern Med. 1996;125(9):723-9.
https://doi.org/10.7326/0003-4819-125-9-199611010-00003.
Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol 2017;8(1):1-20.
https://doi.org/10.5306/wjco.v8.i1.1.
Jain AK, Hughes RS, Sandler AB, Dowlani A, Schwartzberg LS, Dobbs T. A Phase II Study of Concurrent Chemoradiation with Weekly Docetaxel, Carboplatin, and Radiation Therapy Followed by Consolidation Chemotherapy with Docetaxel and Carboplatin for Locally Advanced Inoperable Non-Small Cell Lung Cancer. J Thorac Oncol 2009;4(6):722-7.
Thomas A, Liu SV, Subramaniam DS, Giaccone G. Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol 2015;12(9):511-26.
https://doi.org/10.1038/nrclinonc.2015.90.
Choy H, Safran H, Akerley W, Graziano SL, Bogart JA, Cole BF. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res 1998;4(4):1931–6.
Radiation Therapy Oncology Group. RTOG/EORTC. Late Radiation Morbidity Scoring Scheme. Available from: http://www.rtog.org/ResearchAssociates/AdverseEvent Reporting/RTOG/EORTCLateRadiationMorbidityScoringSchema.aspx. Accessed 8 Sept 2019.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Fort R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-47.
https://doi.org/10.1016/j.ejca.2008.10.026.
Rich AL, Khakwani A, Free CM, Tata LJ, Stanley RA, Peake MD, et al. Non-small cell lung cancer in young adults: presentation and survival in the English National Lung Cancer Audit. QJM: An International Journal of Medicine 2015;108(11):891–7.
https://doi.org/10.1093/qjmed/hcv052.
Price PW, Blackhall F, Lee SM, Ma C, Ashcroft L, Jitlal M, et al. The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. Ann Oncol 2010;21(10):2023–8.
https://doi.org/10.1093/annonc/mdq067.
Huber RM, Flentje M, Schmidt M, Pollinger B, Gosse H, Willner J, et el. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: Study CTRT99/97 by the bronchial carcinoma Therapy group. J Clin Oncol 2006;24(27):4397–404.
https://doi.org/10.1200/JCO.2005.05.4163.
Curran WJ, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011;103(19):1452-60.
https://doi.org/10.1093/jnci/djr325.
Socinski MA. Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer. Oncologist 1999;4(5):408-16.
Park BB, Park JO, Kim H, Ahn YC, Choi YS, Kim K, et al. Is trimodality approach better then bimodality in stage IIIA, N2 positive non-small cell lung cancer? Lung Cancer 2006;53(3):323-30.
https://doi.org/10.3389/fonc.2018.00030.
Bath C. Chemotherapy-induced Peripheral Neuropathy Results in Dose Limiting and Less Chemotherapy Overall. The ASCO post 2013;4(7):13-7.
Dupui LL, Boodhan S, Sung L, Portwine C, Hain R, McCarthy P, et al. Review Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients. Pediatr Blood Cancer 2011;57(2):191–8.
https://doi.org/10.1002/pbc.23114.
Hesketh PJ. Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice. The Oncologist 1999;4(3):191-6.
Lin H, Chen Y, Shi A, Pandya KJ, Yu R, Yuan Y, et al. Phase 3 Randomized Low-Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced Non-Small Cell Lung Cancer. Front Oncol 2016;6(3):260.
https://doi.org/10.3389/fonc.2016.00260.
Takayama K, Inoue K, Tokunaga S, Matsumoto T, Oshima T, Kawasaki M, et al. Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401. Cancer Chemother Pharmacol 2013;72(6):1353-9.
Buccheri G, Ferrigno D. Lung cancer: clinical presentation and specialist referral time. Eur Respir J 2004;24(6):898–904.
https://doi.org/10.1183/09031936.04.00113603.
Barwal VK, Mazta SR, Thakur A, Seam R, Gupta M. Quality of life among lung cancer patients undergoing treatment at a tertiary cancer institute in North India. Int J Res Med Sci 2016;4(11):4903-10.
https://doi.org/10.18203/2320-6012.
Lajendijk JA, Aaronson NK, deJong JMA, tenVelde GPM, Muller MJ, Wouters EF. Prospective Study on Quality of Life Before and After Radical Radiotherapy in Non–Small-Cell Lung Cancer. Inl J Rad Oncol Biol Phy 2000;47(1):149-55.
Liew SM, Sia J, Starmans MHW, Tafreshi A, Harris H, Feigen M, et al. Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non–small cell lung cancer. Cancer Med 2013;2(6):916–24.
https://doi.org/10.1002/cam4.142.
Milovanovic IS, Stjepanovic M, Mitrovic D. Distribution patterns of the metastases of the lung carcinoma in relation to histological type of the primary tumor: An autopsy study. Ann Thorac Med 2017;12(3):191–8.
https://doi.org/10.4103/atm.ATM_276_16.
Emami B, Graham GV: Lung. In: Perez CA, Brady DW (eds): Principles & Practice of Radiation Oncology (3rd ed). Philadelphia, PA, Lippincott-Raven, 1997;1181-1220.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 International Journal of Medicine and Medical Research
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who sent their manuscript to International Journal of Medicine and Medical Research agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License CC-BY-NC that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
2. Authors able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
